Clinical trials: Glial Tumors
Recurrent Glioblastoma
Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma
The purpose of this study is to determine the safety and tolerability of Regorafenib in patients with recurrent or progressive glioblastoma (GBM) who have progressed on bevacizumab.
- Trial name
- NCT04051606
- Testing
- Regorafenib
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Case Comprehensive Cancer Center
Glioblastoma, Glioblastoma, Adult
DNX-2440 Oncolytic Adenovirus for Recurrent Glioblastoma
Patients with first or second recurrence of GBM will be treated with stereotactic injection of the oncolytic virus DNX-2440.
- Trial name
- NCT03714334
- Testing
- DNX-2440 injection
- Where
- Spain
- Volunteers
- 16 people
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
Brain and Central Nervous System Tumors, Cognitive/Functional Effects
Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors
RATIONALE: Methylphenidate may decrease side effects of radiation therapy. It is not yet known if methylphenidate is effective in improving quality of life in patients with primary or metastatic brain tumors.
- Conditions
- Brain and Central Nervous System Tumors, Cognitive/Functional Effects, Depression, Fatigue
- Trial name
- NCT00031798
- Testing
- methylphenidate hydrochloride, quality-of-life assessment, radiation therapy
- Where
- 7 sites in United States
- Sponsor
- Wake Forest University Health Sciences
Astrocytoma, Glioblastoma
Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma
This phase I/Ib trial tests the safety, side effects, and best dose of mycophenolate mofetil in combination with temozolomide and/or radiation therapy (standard of care) in treating patients with glioblastoma.
- Conditions
- Astrocytoma, Glioblastoma, Glioblastoma, IDH-Wildtype, MGMT-Unmethylated Glioblastoma
- Trial name
- NCT05236036
- Testing
- Mycophenolate Mofetil, Quality-of-Life Assessment, Radiation Therapy
- Where
- 3 sites in United States
- Volunteers
- 86 people
- Sponsor
- Northwestern University
Glioma
Clinical Study for the Safety and Therapeutic Efficacy of the AI-QMMM Designed TamavaqTM Personalised Vaccine in Patients With Newly Diagnosed Glioma.
Gliomas are a heterogeneous group of tumors arising from glial cells in the central nervous system and are associated with poor prognosis and significant morbidity.
- Trial name
- TAMAVAQTM (NCT07077616)
- Testing
- Biological: personalized vaccine Based on genetic and transcriptional sequencing information, personalized peptide vaccines would be designed and produced;
- Where
- Greece
- Volunteers
- 29 people
- Sponsor
- Biogenea Pharmaceuticals Ltd.
Glioblastoma
Dose Escalation Radiotherapy With Modulation of Intensity and Integrated Boost (SIB-IMRT) in the Treatment of Glioblastomas in Adults
The main goal of this study is to evaluate and to determine the dose of a highly accurate irradiation (allowing to increase the dose delivered while restricting the risk of complication) in association with temozolomide.
- Trial name
- SIB-IMRT (NCT01043536)
- Testing
- radiotherapy, temozolomide
- Where
- France
- Volunteers
- 10 people
- Sponsor
- Centre Georges Francois Leclerc
Malignant Glioma of Brain
Study of Acetazolamide With Temozolomide in Adults With Newly Diagnosed or Recurrent Malignant Glioma
This is a Phase I study that examines the rate of dose limiting side effects in patients with malignant astrocytoma treated with combination acetazolamide (ACZ) and temozolomide (TMZ).
- Trial name
- NCT03011671
- Testing
- Acetazolamide, Temozolomide
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Chicago
High-grade Glioma, Lung Cancer
A Proof-of-concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and Angiogenesis
This proof-of-concept study is designed to assess the ability of [18F]AH-111585 PET imaging to detect tumors and angiogenesis. Up to 30 evaluable subjects are planned to be included at up to 2 study centers in the US.
- Conditions
- High-grade Glioma, Lung Cancer, Head & Neck Cancer, Sarcoma
- Trial name
- NCT00565721
- Testing
- Fluciclatide Injection - (AH111585 (F18))
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- GE Healthcare
Glioblastoma
Exercise in Patients With Glioblastoma
Patients with newly-diagnosed GBM will be given personalized exercise regimes during concurrent chemo-radiation and up to 3 months later.
- Trial name
- NCT03390569
- Testing
- Exercise
- Where
- Canada
- Volunteers
- 54 people
- Sponsor
- University Health Network, Toronto
Progressive Glioblastoma, Recurrent Glioblastoma
Sonodynamic Therapy With SONALA-001 or 5-ALA HCL and Magnetic Resonance Guided Focused Ultrasound for the Treatment of Progressive or Recurrent Glioblastoma
This early phase I trial tests the safety, best dose, and effectiveness of SONALA-001 or 5-ALA HCL in combination with magnetic resonance imaging-guided focused ultrasound (MRgFUS), also called sonodynamic therapy, in treating…
- Trial name
- NCT07076472
- Testing
- Aminolevulinic Acid Intravenous Formulation SONALA-001, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Mayo Clinic
Brain and Central Nervous System Tumors
Procarbazine in Treating Patients With Recurrent Brain Tumor
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of procarbazine in treating patients who have…
- Trial name
- NCT00004004
- Testing
- procarbazine hydrochloride
- Where
- 10 sites in United States
- Sponsor
- New Approaches to Brain Tumor Therapy Consortium
Glioma, BRAF V600E
A Biospecimen Collection Study in BRAF-V600E Mutated Recurrent Gliomas
This is a surgical biospecimen collection study. The purpose of this study is to understand how much of two drugs (dabrafenib and trametinib) are able to penetrate brain tumors and turn off the RAF signaling pathway.
- Conditions
- Glioma, BRAF V600E, Pleomorphic Xantho-Astrocytoma, Glioblastoma
- Trial name
- NCT03593993
- Testing
- Surgical Cohort
- Where
- 5 sites in United States
- Volunteers
- 3 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Adult Medulloblastoma
Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma
This phase II trial is studying how well vismodegib works in treating adult patients with recurrent or refractory medulloblastoma.
- Trial name
- NCT00939484
- Testing
- Pharmacological Study, Vismodegib
- Where
- 13 sites in United States
- Volunteers
- 31 people
- Sponsor
- National Cancer Institute (NCI)
Pediatric Malignant Brain Tumor -Diffuse Intrinsic Pontine Glioma
Palliative Re-irradiation for Progressive Diffuse Intrinsic Pontine Glioma (DIPG) in Children
Although DIPG is not curable, re-irradiation with a modest total dose and short treatment time provides good palliation of symptoms, improves quality of life, delays disease progression and has minimal and manageable toxicity.
- Trial name
- NCT01777633
- Testing
- Palliative re-irradiation for progressive DIPG in children
- Where
- Israel
- Volunteers
- 15 people
- Sponsor
- Hadassah Medical Organization
Brain and Central Nervous System Tumors, Unspecified Childhood Solid Tumor, Protocol Specific
Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as temozolomide, vincristine, and irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00138216
- Testing
- irinotecan hydrochloride, temozolomide, vincristine sulfate
- Where
- 18 sites in United States, Canada
- Volunteers
- 42 people
- Sponsor
- Children's Oncology Group
Solid Tumor, Solid Carcinoma
Imaging of Solid Tumors Using 18F-TRX
This phase I trial tests the safety and effectiveness of 18F-TRX in detecting tumors (cancer) patients with solid tumors. 18F-TRX is an imaging tracer that is used to visualize tumors using a PET scan.
- Conditions
- Solid Tumor, Solid Carcinoma, Castration-Resistant Prostate Carcinoma, Locally Advanced Clear Cell Renal Cell Carcinoma
- Trial name
- NCT06942104
- Testing
- 18F-TRX, Positron Emission Tomography (PET)/Computerized tomography (CT), Tumor Biopsy
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Rahul Aggarwal
Glioma
Tumor Hypoxia and Proliferation in Patients With High-Grade Glioma
This is a pilot study to assess a new methodology developed for High Grade Glioma (HGG). FMISO PET (Fluoromisonidazole-PET) allows researchers to study whether tumor cells lack oxygen (hypoxia).
- Trial name
- NCT04309552
- Testing
- 18F-FMISO PET, 18F-FLT PET
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Weill Medical College of Cornell University
Epilepsy, Glioma
Correlation Between SV2A Expression in Tumour Tissue and Efficacy of Levetiracetam in Glioma Patients With Epilepsy
The purpose of this study is to investigate the correlation of SV2A expression in surgically removed tumour and tumour-surrounding tissue of glioma patients suffering from epilepsy with their clinical response to levetiracetam.
- Trial name
- NCT00454935
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- Amsterdam UMC, location VUmc
Glioblastoma
Early Diagnosis of Pseudoprogression Using 11C-Methionine PET-MRI After Concomitant Radiochemotherapy Treatment for Glioblastoma.
Pseudoprogression is a phenomenon related to post-treatment rearrangements (including radiation necrosis). It appears early in the first year after treatment and accounts for 30 to 50% of patients followed with glioblastoma.
- Trial name
- TIGRE (NCT03739333)
- Testing
- 11C-Methionine PET-MRI
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Hospices Civils de Lyon
Glioblastoma, Brain Neoplasm
Bevacizumab With or Without Surgery for Adult Glioblastomas
Background: Glioblastoma (GBM) is the most common malignant brain tumor in adults. Patients with GBM are usually treated with surgery, radiation, and chemotherapy. Despite this treatment, most GBMs start growing again.
- Trial name
- NCT01413438
- Testing
- Craniotomy
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.